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Abstract. Patients with recurrent and/or metastatic squamous 
cell carcinoma of the head and neck (R/M SCCHN) have a 
poor prognosis. Over the past decade, a major development in 
the first‑line treatment of R/M SCCHN was the introduction 
of cetuximab in combination with platinum plus 5‑fluorouracil 
chemotherapy. Currently, a promising novel treatment option 
in R/M SCCHN has emerged, termed immune checkpoint 
inhibitors. However, only a few patients presenting with R/M 
SCCHN have exhibited meaningful tumor regression with 
these agents. Therefore, novel agents are required to order 
improve the overall survival of patients with R/M SCCHN. 
Recently, we demonstrated that R/M SCCHN cells are highly 
sensitive to eribulin. In the present study, the effects of 
eribulin, paclitaxel and vinblastine were investigated in R/M 
SCCHN (OLC-01 and OSC-19) and locally advanced SCCHN 
(OSC-20) cells. Tumour-inhibitory activities of eribulin 
against R/M SCCHN were evaluated in orthotopic xenograft 
models. The data revealed that eribulin has sub-nM growth 
inhibitory activities in vitro against OLC-01 cells, and that it 
is more potent than paclitaxel and vinblastine. The reduced 
expression of Tubulin Beta 3 Class III (TUBB3) following 
treatment was correlated with a high sensitivity to eribulin. 
Histological analysis of OLC-01 cells in NOD-SCID mice 
demonstrated that they had a higher invasiveness in the tissue 
around the alveolar cancer when compared with the histology 
of OSC-19 cells, which has been reported in our previous 
study. Treatment with eribulin revealed marked inhibi-
tory activities in vivo at 0.125 mg/kg against OLC-01 cells 
orthotopic xenografts. In conclusion, the results highlight the 
existence of invasive-type heterogeneity in R/M SCCHN with 
respect to eribulin sensitivity. Eribulin is already an approved 
clinical agent; therefore, the continued investigation of its 
preclinical antitumor attributes may contribute significantly 
to the future process of identifying novel uses of eribulin 
against R/M SCCHN.
Introduction
Patients with recurrent and/or metastatic squamous cell 
carcinoma of the head and neck (R/M SCCHN) have a poor 
prognosis with a median overall survival (OS) time of less than 
1 year (1). Cetuximab in combination with cisplatin/carboplatin 
and 5‑fluorouracil, as a first‑line treatment of R/M SCCHN, 
followed by maintenance treatment with cetuximab 
(EXTREME regimen) has exhibited the most favourable 
results with respect to overall response rates, progression-free 
survival and OS time (2,3). A variation of this regimen permits 
the replacement of 5‑fluorouracil with a taxane (e.g., docetaxel, 
paclitaxel) (4,5). Meanwhile, immune checkpoint inhibitors 
have emerged as promising novel treatment options for R/M 
SCCHN based on their positive results in clinical trials of 
second-line treatment (6,7). These monoclonal antibodies 
targeting epidermal growth factor receptor or programmed 
death 1 (PD-1) were beneficial in palliative and curative 
treatments. However, few patients with R/M SCCHN exhibit 
meaningful tumour regression in response to these agents, and 
almost all responders develop acquired resistance against the 
tumour following 2-3 months of treatment (8). In addition, 
hyper-progression was noted in 29% of patients with R/M 
SCCHN who received anti‑PD‑1 agents, and this finding was 
correlated with a shorter progression-free survival time (8). 
Hyper-progression was also observed in 39% of patients with 
locoregional recurrence and in 9% of patients with only distant 
metastases (8). Therefore, inhibitors or molecules that disrupt 
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known molecular pathways involved in R/M SCCHN are of 
particular interest, either as monotherapies or combination 
therapies.
Eribulin, and its mesylate salt (Halaven, Eisai), is an 
analogue of halichondrin B, which is obtained from a marine 
sponge (9). As the first cancer therapeutic drug in the class 
halichondrin, eribulin acts by inhibiting microtubule dynamics 
and has a distinct mode of action against other tubulin-targeted 
agents (10‑12). The drug specifically binds to the plus ends of 
microtubules with high affinity, resulting in the formation of 
short, non-functional tubulin aggregates that suppress micro-
tubule dynamic stability and inhibit microtubule growth (13). 
This leads to mitotic arrest by disrupting the formation of 
normal mitotic spindles and subsequently leads to cancer 
cell apoptosis (10). Pre-clinically, eribulin exhibits potent 
activity towards various human cancer cell types in vitro and 
in vivo (9), exerting its anticancer effects by inducing irrevers-
ible mitotic blockade (14), subsequently leading to cancer cell 
apoptosis (13).
It has recently been demonstrated that R/M SCCHN cells 
were highly sensitive to eribulin in comparison with other 
SCCHN cell lines, and treatment with eribulin significantly 
enhanced the anti-proliferative effects of cetuximab (15). 
Eribulin is currently approved for the treatment of recurrent 
metastatic breast cancer, as it improves OS time in patients with 
late-stage metastatic disease (16). The present study evaluated 
eribulin as a novel therapeutic agent for R/M SCCHN.
Materials and methods
Cell culture. Three SCCHN cell lines established from 
biopsies of patients with R/M SCCHN or locally advanced 
SCCHN (LA-SCCHN) with different grades of invasiveness 
were used, including OLC-01 cells (R/M SCCHN, high-grade 
invasiveness), which were newly established in the present 
study, as well as the previously described OSC-19 (R/M 
SCCHN, intermediate-grade invasiveness) (17,18) and OSC-20 
cells (LA-SCCHN, low-grade invasiveness) (19). The OLC-01 
cells were derived from a 62-year-old female with SCCHN, 
involving the maxillary gingiva and lower lip, high-grade 
invasiveness that had metastasised to the cervical lymph nodes 
and recurred frequently. Tissue samples were treated with 
5% bacterial collagenase type I (Worthington Biochemical 
Corporation, Freehold, NJ, USA) for 1 h at 37˚C and 0.02% 
trypsin (Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
for 30 min at 37˚C (17). Subsequently, the activities of the 
proteinases were blocked with 10% foetal bovine serum (FBS; 
Hyclone; GE Healthcare Life Sciences, Logan, UT, USA), 
the cells were seeded in culture dishes and maintained in 
Dulbecco's modified Eagle's medium (DMEM; Sigma‑Aldrich; 
Merck KGaA, Darmstadt, Germany) containing 10% FBS 
at 37˚C in a humidified 5% CO2 atmosphere. Cell clusters 
became attached to culture dishes in 24 h with an efficiency of 
~90%. Cells began to grow continuously at 5 months following 
cultivation. No fibroblast outgrowth was observed. The 
doubling times of OLC-01 cells cultured on plastic dishes was 
24.7 h, and the OLC-01 cells had little intercellular connecting 
apparatus. OSC-19 (JCRB #0198) and OSC-20 cells (JCRB 
#0197) and normal human oral fibroblasts of the lip mucosa 
(KD; JCRB #9103) were obtained from the JCRB Cell Bank 
(Osaka, Japan). All cell lines were grown in DMEM (high 
glucose; Sigma-Aldrich; Merck KGaA) supplemented with 
10% heat-inactivated FBS at 37˚C in a humidified atmosphere 
containing 5% CO2. Experiments using human samples were 
approved by the Ethics committee of the Kanazawa University 
Graduate School of Medical Science (IRB No. 352-2), and 
written informed consent was obtained from patients providing 
tissue specimens.
Proliferation assay. The three SCCHN cell lines were plated 
in 96-well plates and cultured with 0, 0.01, 0.1, 1, 5, 10 nM 
of eribulin, paclitaxel and vinblastine for 3 days respectively, 
followed by cell number and viability determinations using the 
CellTiter 96 AQueous One Solution Cell Proliferation Assay 
(Promega Corporation, Madison, WI, USA) according to the 
manufacturer's protocols. The optical density at 490 nm was 
measured using a microplate reader (iMark microplate reader; 
BioRad Laboratories, Inc., Hercules, CA, USA). Mean IC50 
values were calculated based on those generated from separate 
sigmoidal curves representing the growth inhibition activity 
vs. eribulin, paclitaxel and vinblastine in three independent 
experiments. Eribulin was purchased from Eisai Co., Ltd. 
(Tsukuba, Japan). Vinblastine and paclitaxel (Taxol) were 
purchased from Nihon Kayaku (Tokyo, Japan). The data are 
presented as the mean ± SEM.
RNA extraction, cDNA synthesis, and quantitative reverse 
transcription‑quantitative polymerase chain reaction 
(RT‑qPCR). The mRNA expression levels of TUBB, TUBB2A, 
TUBB3, TUBB4B and TUBB6 in the three SCCHN cell lines 
treated with eribulin, paclitaxel and vinblastine at concentra-
tion of IC50 or the control vehicle-treated SCCHN cells were 
analysed using a Rotor-Gene Q 2plex System (Qiagen, Hilden, 
Germany) with FAM/ZEN/IBFQ labelled TaqMan probes 
(Integrated DNA Technologies Inc., Coralville, IA, USA; 
DNA sequences not available). Total RNA was extracted from 
the SCCHN cells using TRI Reagent (Merck KGaA) and 
a PureLink RNA Mini kit (Thermo Fisher Scientific, Inc.). 
cDNA was obtained using a PrimeScript 1st strand cDNA 
Synthesis kit (Takara Biotechnology, Inc., Tokyo, Japan). All 
reactions were performed in accordance with the manufactur-
er's protocol. For the ΔΔCt method for quantitative real-time 
PCR (qPCR) to be valid, the efficiency of the target amplifica-
tion and the efficiency of the reference amplification must be 
approximately equal. Therefore, the present study analysed 
HPRT1, B2M, TBP, GUSB, ACTB, POLR2A, RPLP0, PPIA 
and 18S rRNA as potential internal standards for analysing 
TUBB, TUBB2A, TUBB3, TUBB4B and TUBB6 expression. 
Based on these validation experiment, we selected PPIA as 
an internal standard using HEX/ZEN/IBFQ labelled TaqMan 
probes (Integrated DNA Technologies Inc.; DNA sequences 
not available). Relative expression levels were calculated using 
the ΔΔCq method for qPCR (20), which presents the data as 
fold differences in expression relative to a calibrator sample, 
in this case represented by the mean expression of three 
experimental measurements of PPIA in the control or control 
vehicle-treated cells.
Western blot analysis. Total protein was extracted from the 
three SCCHN cell lines treated with eribulin, paclitaxel and 
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vinblastine at concentration of IC50 or the control vehicle-treated 
SCCHN cells. The concentration of total extracted protein 
was measured using the Fluorescence Qubit Protein assay 
in accordance with the manufacturer's protocol (Thermo 
Fisher Scientific, Inc.). An equal amount (30 µg of protein) 
of lysate or culture medium was mixed with loading buffer 
and then electrophoretically separated using 10% SDS-PAGE 
gel and transferred onto PVDF membranes. The membranes 
were blocked with Blocking One (Nacalai Tesque, Kyoto, 
Japan) for 10 min at room temperature, followed by incuba-
tion with anti-TUBB3 (cat. no. 52623; Abcam, Tokyo, Japan) 
and anti-human GAPDH antibodies (cat. no. M171-3; MBL, 
Tokyo, Japan). Following washing with tris-buffered saline 
containing 0.05% Tween, the membranes were incubated 
with horseradish peroxidase-conjugated anti-mouse IgG 
(cat. no. 7076; Cell Signalling Technology, Inc., Danvers, MA, 
USA). After washing with tris-buffered saline-0.05% Tween, 
membranes were incubated with the ECL Prime Western 
Blotting Detection Reagent (GE Healthcare, Little Chalfont, 
UK). Signals were detected and analysed using C-DiGit 
(M&S TechnoSystems, Tokyo, Japan).
In vivo orthotopic xenograft studies. The anticancer 
effects of eribulin, paclitaxel and vinblastine were evalu-
ated in OLC-01 human R/M SCCHN xenograft models 
using 5-6 week-old female NOD-SCID mice (NOD.
CB17-Prkdcscid/J, Charles River Japan, Yokohama, Japan). 
The mice were housed at 22±2˚C, ammonia ≤14 ppm, 12‑h 
light/12-h dark cycle, free access to food and water and 
free from microbial pathogens at the Animal Center of 
Kanazawa University (Kanazawa, Japan). All of the studies 
using laboratory animals were approved by the Institutional 
Animal Care and Use Committees of Kanazawa University 
(permit No. AP183935), and the protocols adhered to all 
applicable institutional and governmental guidelines for 
the humane care and use of laboratory animals. At three 
days prior to drug administration, 1x106 OLC-01 cells were 
injected submucosally into the tongues of mice. Eribulin, 
paclitaxel and vinblastine were administered intravenously 
at concentrations of 0.125 and 0.5 mg/kg body weight three 
times at intervals of 2 days (q2d x 3). On day 7, the mice were 
sacrificed by intraperitoneal administration of 100 mg/kg 
Nembutal (Dainippon Sumitomo Pharma Co., Ltd, Osaka, 
Japan) due to the high tumour load and feeding difficulties. 
The maximum size the tumours were permitted to grow to 
was 56.8 mm3. Soft food (DietGel 76A, ClearH20, Portland, 
ME) was placed on the cage floor every day following the 
inoculation of cells until sacrifice. Each group consisted 
of six mice. Tumour volumes were determined via calliper 
measurements and calculated using the formula V=0.67π[(L 
+ W)/4]3 [i.e., volume (V) of a semisphere with a diameter 
equal to the mean of tumour length (L) and width (W)] (9). 
Body weights and water consumption were measured in all 
experiments to assess toxicity. 
Each tumour specimen was fixed in 10% buffered formalin 
for 16 h at room temperature and embedded in paraffin to 
prepare 4 µm-thick sections. The sections were stained with 
haematoxylin for 3 min and eosin for 30 sec at room tempera-
ture. The stained sections were then observed under a light 
microscope (magnification, x100).
Statistical analysis. The data are presented as the 
mean ± standard error of the mean. For comparisons between 
samples, data were analysed by one-way analysis of variance 
and Tukey's multiple comparison tests using SPSS, version 23 
(IBM Corp., Armonk, NY, USA). P<0.05 was considered to 
indicate a statistically significant difference. 
Results
Inhibition of human R/M SCCHN cell growth in vitro. The 
present study examined the effects of eribulin on the prolif-
eration of three SCCHN cell lines. On the basis of the known 
anti-tubulin mechanism of eribulin (21), the in vitro growth 
inhibitory effects of eribulin were compared with those of the 
microtubule stabiliser paclitaxel and microtubule destabiliser 
vinblastine (Fig. 1). The IC50 of eribulin in OLC-01 cells was 
0.063±0.008, compared with 0.512±0.06 and 5.673±1.765 nM 
in OSC-19 and OSC-20 cells, respectively (Fig. 1 and Table I). 
In OLC-01 cells, eribulin inhibited cell growth with greater 
potency than paclitaxel (3.366±0.419 nM) or vinblastine 
(0.534±0.114 nM) (Fig. 1 and Table I) . In OSC-19 cells, 
eribulin had greater potency than paclitaxel (6.224±0.779 nM) 
(Fig. 1 and Table I). Meanwhile, OSC-20 cells were approxi-
mately 10-50-fold less sensitive to eribulin and vinblastine 
than OLC-01 and OSC-19 cells, a difference that was not 
observed for paclitaxel (Fig. 1 and Table I).
Eribulin decreased TUBB3 expression in OLC‑01 cells. 
β-tubulin subunits affect microtubule polymer mass 
and/or drug binding, and they are associated with resistance 
to tubulin-binding agents (22-24). Previous research using 
gene expression profiling revealed that the TUBB, TUBB2A, 
TUBB3, TUBB4B and TUBB6 genes can selectively differ-
entiate eribulin-sensitive several cancer cells (25). Therefore, 
the differences in of the expression of these β-tubulin subunits 
in SCCHN cells were analysed by RT-qPCR in order to 
analyse the mechanism of high sensitivity of OLC-01 cells to 
eribulin, as presented in Fig. 1 and Table I. In OLC-01 cells, 
TUBB3 levels were 1.9-, 2.0- and 1.5-fold higher than those 
in OSC-19, OSC-20 and KD cells, respectively (Fig. 2A). In 
addition, TUBB4 levels were markedly higher in OLC-01 cells 
than in KD cells. By contrast, TUBB and TUBB2A expres-
sion in OLC-01 was 0.46- and 0.55-fold lower, respectively, 
than that in KD cells. TUBB4B expression was 1.73-fold 
higher in OSC-19 cells than in KD cells. In addition, the levels 
Table I. The effects of microtubule inhibitors on SCCHN cell 
lines.
 IC50 (nM)
 ------------------------------------------------------------------------------------------
Drug OSC-20 OSC-19 OLC-01
Eribulin 5.673 (1.765) 0.512 (0.060) 0.063 (0.008)
Paclitaxel 6.924 (0.513) 6.224 (0.779) 3.366 (0.419)
Vinblastine 3.263 (0.372) 0.511 (0.058) 0.534 (0.114)
Values are expressed as the mean (SEM).
KOBAYASHI et al:  ERIBULIN TARGETS INVASIVE HEAD AND NECK CANCER 5067
of TUBB2A and TUBB4B in OSC-20 cells were 1.7- and 
2.42-fold higher, respectively, than those in KD cells (Fig. 2A).
As presented in Fig. 2B, TUBB3 and TUBB levels in 
OLC-01 cells were significantly decreased under eribulin 
treatment compared with the control levels. Conversely, the 
expression of five β-tubulin subunits (TUBB, TUBB2A, 
TUBB3, TUBB4B and TUBB6) in OSC-19 cells and four 
β-tubulin subunits (TUBB, TUBB3, TUBB4B and TUBB6) in 
OSC‑20 cells were significantly increased following eribulin 
treatment. There was large variation in the fold changes in 
the individual cell lines under paclitaxel treatment; however, 
the expression of the majority of β-tubulin subunits was 
Figure 1. Inhibition of human SCCHN cell growth in vitro using eribulin, paclitaxel and vinblastin. (A) The growth inhibitory effects of OLC-01 cells treated 
with eribulin, paclitaxel and vinblastin were compared with those of OSC-20 and OCC-19 cells. The data are presented as the mean ± standard error of the 
mean from triplicate experiments. (B) The growth inhibitory effects of eribulin against three human SCCHN cell lines were compared with those of the 
microtubule stabiliser paclitaxel and microtubule destabiliser vinblastine. The data are presented as the mean ± standard error of the mean from triplicate 
experiments. SCCHN, squamous cell carcinoma of the head and neck.
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significantly increased by >1.3‑fold in the three cell lines. 
Similarly, TUBB3 expression was significantly decreased by 
vinblastine treatment in OLC-01 and OSC-19 cells vs. the 
control (Fig. 2B). As illustrated in Fig. 2C, western blot anal-
ysis revealed that TUBB3 expression was downregulated in 
eribulin- or vinblastine-treated OLC-01 cells compared with 
those in OSC-19 and OSC-20 cells. In addition, treatment with 
paclitaxel upregulated TUBB3 expression in all three SCCHN 
cell lines.
Inhibition of human SCCHN orthotopic xenograft tumour 
growth in vivo. The abilities of eribulin to inhibit tumour growth 
in vivo were examined in human SCCHN orthotopic xenograft 
models created using OLC-01 cells (Fig. 3). On day 7, treatment 
with 0.125-0.5 mg/kg eribulin led to >95% growth inhibition 
compared with the findings in untreated tumours (Fig. 3A 
and B). Contrarily, paclitaxel had weaker growth inhibitory 
effects at these concentrations on day 7; and no measurable 
effects were observed at 0.125 mg/kg, whereas the concentra-
tion of 0.5 mg/kg inhibited growth by 54.6% compared with 
the untreated control (Fig. 3A and B). Meanwhile, treatment 
with 0.125-0.5 mg/kg vinblastine inhibited tumour growth 
by 35.5-73.3% vs. the control (Fig. 3A and B). There was no 
evidence of toxicity based on body weight or water consumption 
(data not shown). As presented in Fig. 3C, histologic analysis 
of OLC-01 cells implanted into NOD-SCID mice revealed 
that cord-like small alveolar tumour lesions had greater diffu-
sion and invasion into the tissue surrounding the tumour than 
previously reported for OSC-19 cells (18). In addition, tumours 
treated with eribulin alone displayed increasing numbers of 
abnormal mitotic cells (arrowheads) (26,27), suggesting that 
eribulin may have an inhibitory effect on the microtubule 
dynamics of tumour cells. Tumour necrosis was identified only 
in the eribulin group (arrows). Haematoxylin and eosin staining 
revealed no pathological changes in the untreated, paclitaxel 
and vinblastine groups (Fig. 3C).
Figure 2. TUBB, TUBB2A, TUBB3, TUBB4B and TUBB6 expression in squamous cell carcinoma of the head and neck cell lines. (A) RT-qPCR of TUBB, 
TUBB2A, TUBB3, TUBB4B and TUBB6 mRNA derived from OLC-01, OSC-19 and OSC-20 cells, presented as fold changes relative to the expression in KD 
cells. *P<0.05 vs. control KD cells. (B) RT-qPCR of TUBB, TUBB2A, TUBB3, TUBB4B and TUBB6 mRNA derived from untreated and eribulin-, paclitaxel- 
or vinblastine-treated OLC-01, OSC-19 and OSC-20 cells. Data are presented as fold changes in treated cells relative to the expression in untreated control cells. 
*P<0.05 vs. control vehicle-treated OLC-01, OSC-19 and OSC-20 cells. (C) Immunoblot of untreated and eribulin-, paclitaxel or vinblastine-treated lysates 
of OLC-01, OSC-19, and OSC-20 cells using antibodies against TUBB3. GAPDH served as the loading control. RT-qPCR, reverse transcription-quantitative 
polymerase chain reaction analysis; Cont, control; ERI, eribulin; PTX, paclitaxel; VBL, vinblastine.
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Discussion
The traditional approach to drug discovery involves the de novo 
identification and validation of novel molecular entities, which 
is a time-consuming and costly process. Drug repositioning, the 
process of identifying novel uses for existing drugs, has gained 
popularity in recent years. Recently, we demonstrated that R/M 
SCCHN cells were highly sensitive to eribulin in comparison 
with other SCCHN cell lines (15), leading us to examine the 
efficacy of the drug against this malignancy in the present study.
In previous in vitro studies, cell growth was observed to be 
inhibited by eribulin (IC50=0.09-9.5 nM) in a wide variety of 
established human cancer cell lines, including breast, non-small 
cell lung, small cell and ovarian cancer cell lines (9,28). In 
these reports, eribulin was observed to inhibit MDA-MB-435 
cell growth (IC50=0.09 nM) with greater potency than vinblas-
tine (IC50=0.59 nM) or paclitaxel (IC50=2.5 nM) (9), which 
were in line with the findings of the present study. Meanwhile, 
the sensitivity of OSC-19 and OSC-20 cells to eribulin in the 
present study was similar or lower than that previously reported 
for breast cancer cells (9). Additional studies are necessary to 
elucidate the precise molecular mechanisms governing this 
selective eribulin sensitivity.
Eribulin binds near a region called the Vinca-binding 
domain of β-tubulin at microtubule plus ends (22). The binding 
site for paclitaxel is located in a β-tubulin subunit on the whole 
Figure 3. Inhibition of human squamous cell carcinoma of the head and neck xenograft growth in vivo by eribulin. (A) Antitumor activity of eribulin, paclitaxel 
or vinblastine was evaluated against OLC-01 xenografts using the indicated concentrations. Dosing days for drugs are illustrated with arrows below the X-axes. 
Plotted mean change in the target lesion from baseline (%) following the onset of complete remission. Results are presented as the mean ± SEM. *P<0.05 vs. 
0 mg/kg. (B) Representative tongue images at the end of the treatment schedule. Scale bar, 1 mm. (C) Representative H&E-stained histological images of 
OLC-01 xenografts at the end of the treatment schedule. Abnormal mitotic cells are denoted by arrow heads. Necrosis is indicated by arrows. Scale bar, 50 µm.
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inner surface of the microtubule (23). Vinblastine binds to a 
subunit of β-tubulin dimers on the whole outside surface of the 
microtubule (24). These differences in the drug binding region 
may be linked to alterations of the β‑tubulin expression profile, 
particularly changes in expression of the TUBB3 isotype, and 
drug sensitivity. Of note, Wilson et al (29) reported that erib-
ulin had an increased binding affinity for microtubules in the 
absence of TUBB3. TUBB3 is primarily expressed in neurons 
and the testes (30). The potential association of TUBB3 over-
expression with cancer aggressiveness or metastasis has been 
reported for several cancer types, including non-small-cell 
lung cancer (31), breast cancer (32), urinary bladder 
cancer (33) and oesophageal adenocarcinoma (34). Notably, 
Nienstedt et al (35) reported that TUBB3 is over-expressed in 
the majority of head and neck cancers; however, this expres-
sion is not associated with clinical outcome. The precise role of 
TUBB3 in R/M SCCHN prior to eribulin treatment is unclear. 
However, previous studies have demonstrated that α- and 
β-tubulin synthesis is auto-regulated by post-transcriptional 
mechanisms that can alter tubulin mRNA levels in response 
in the unassembled tubulin subunit concentration (36). Based 
on these findings, the uregulation of tubulin expression by 
paclitaxel observed in the present study is likely driven by a 
compensatory mechanism to increase the supply of tubulin 
monomers depleted by microtubule polymerisation, whereas 
the downregulation of tubulin expression by eribulin may 
be explained by the opposite effect of increasing the number 
of tubulin monomers by inhibiting microtubule polymerisa-
tion (37). Consequently, it is reasonable to infer that sensitivity 
to eribulin may be associated with the downregulation of 
TUBB3 expression rather than the heterogeneous expression 
level of TUBB3 in patients with R/M SCCNH prior to eribulin 
treatment.
Previous studies of human tumour xenograft studies in 
mice, including breast, lung, ovary, colon, melanoma, pancre-
atic and fibrosarcoma, have demonstrated tumour regression, 
remission and an increased lifespan at concentrations below 
the maximum tolerated dose of eribulin (9,28). Eribulin 
exhibits significant and superior in vivo anticancer efficacy 
in MDA-MB-435, COLO 205 and LOX cells at much lower 
concentrations (0.05-1 mg/kg i.v. or i.p.) than paclitaxel. All 
concentrations of eribulin used in the OLC-01 xenograft model 
in the present study were equally efficacious (0.125, 0.5 mg/kg) 
to those in an MDA-MB-435 model (9,28). Despite the excel-
lent sensitivity of R/M SCCNH cells to the drug in the present 
study, a Phase II study of eribulin in patients with R/M SCCHN 
did not reveal significant efficacy (38). A multi-centre Phase II 
trial evaluating the response to eribulin in patients with R/M 
SCCHN was conducted in conjunction with the NCI (38). In 
total, 40 eligible patients with a median age of 61.2 years were 
enrolled, 33 (83%) of whom had metastatic disease. The primary 
tumour sites included the oropharynx, lip/oral cavity, larynx, 
hypopharynx, other/unknown and nasopharynx in 15, 12, 6, 4, 2 
and 1 patient(s), respectively. The best response to eribulin was 
stable disease/no response in 48% of patients, whereas disease 
worsening was noted in 48% of patients. In total, 5% of patients 
had a confirmed partial response, and 3% had an unconfirmed 
partial response. OSC-19 cells were established from tumour 
biopsies of patients with R/M SCCHN (17,18). In addition, 
OLC-01 cells established from tumour biopsies of patients 
with R/M SCCHN in this previous study were more invasive 
than OSC-19 cells (17,18). Indeed, the histology of OLC-01 
xenografts in NOD-SCID mice in the present study was in line 
with previous findings (18). These data suggested that eribulin 
had selectively high efficacy against R/M SCCHN cells with 
high invasiveness. At present, it is unclear whether patients 
enrolled in a recent Phase II trial had high-grade invasive R/M 
SCCHN (38). Alternatively, eribulin treatment converted R/M 
SCCHN cells into an epithelial phenotype, as reported in our 
previous study (15), whereas OSC-20 cells, which possess 
an epithelial phenotype, exhibited eribulin resistance in the 
present study. These results suggested that eribulin sensitivity 
decreases during mesenchymal-to-epithelial transition. To 
completely inhibit R/M SCCHN tumour growth, combination 
therapy consisting of eribulin plus cetuximab may be useful 
due to eribulin sensitising R/M SCCHN cells to cetuximab 
via induction of mesenchymal-to-epithelial transition as 
demonstrated previously (15).
In conclusion, the results of the present study suggest the 
existence of invasive-type heterogeneity in R/M SCCHN with 
respect to eribulin sensitivity, suggesting that further studies 
comparing characteristics of SCCHN models as a function 
of eribulin sensitivity may illuminate potential biomarker 
approaches for defining eribulin sensitivity and resistance. As 
a clinically approved drug, the continued investigation of the 
preclinical antitumor attributes of eribulin may significantly 
contribute to future progress in identifying novel uses of 
eribulin against R/M SCCHN.
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